English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

This study aims to investigate the association between antihypertensive use and the risk of cataract in a matched case-control study. We analysed the Korean National Health Insurance Service-Health Screening Cohort database from 2002 to 2013. We defined ‘cases’ as patients prescribed antihypertensives and underwent their first eye cataract surgery between 2010 and 2013. ‘Controls’ were patients prescribed antihypertensives and no history of cataract surgery or diagnosis between 2002 and 2013. Four controls were matched to each case by several variables. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated for cataract risk using a conditional logistic regression model after adjustment. The analyses comprised 12,166 cases and 48,664 controls. The adjusted ORs for cataracts were 1.18 (95% CI: 1.12–1.24) in thiazide diuretics, 1.12 (95% CI: 1.07–1.18) in beta-blockers, 0.94 (95% CI: 0.90–1.00) in calcium channel blockers, 1.22 (95% CI: 1.14–1.30) in angiotensin-converting enzyme (ACE) inhibitors, and 0.97 (95% CI: 0.91–1.03) in angiotensin II receptor blockers compared to ‘non-use’ of each antihypertensive. In a nationwide case-control study, the use of thiazide diuretics, beta-blockers, or ACE inhibitors do not represent minimal clinical important difference in the risk of cataract and the use of calcium channel blockers or angiotensin II receptor blockers is not associated with an increased risk of cataracts compared to non-use of each antihypertensive. Given the benefits of treating hypertension, such as the reduction in further complications, we suggest there is no need to change current clinical practice for antihypertensives.

Antihypertensive Use and the Risk of Cataract in Patients with Hypertension: A Nationwide Case-control Study